One each from South Korea, China and Canada
Suven Life Sciences announced that the Company has received the grant of one (1) product patent from South Korea (10-1386354), one (1) product patent from China (CN102639526) and one (1) product patent from Canada (CA 2737282) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2029, 2029 and 2031 respectively.The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia.
With these new patents, Suven has a total of fourteen (14) granted patents from South Korea, fourteen (14) granted patents from China and sixteen (16) product patents from Canada.
Powered by Capital Market - Live News